Replies to post #141671 on Biotech Values

[DewDiligence]

…assuming no generics and no BG-12 launch, mid upper bound [of 2012 US Copaxone sales] should be met.

Inasmuch as the BG-12 NDA was submitted on 2/28/12 (#msg-72621306) and it is undergoing a standard review, there’s essentially no chance of meaningful US sales of BG-12 during 2012.